Table 2 Top pathways based on differentially expressed genes between day 1 and 14 in CP vs Control cases.
Pathway Name | p-value | FDR | Perturbed Genes | Notes | |
|---|---|---|---|---|---|
Unique to CP | Huntington Disease | 4.593e–5 | 0.008 | Upregulated: VDAC2, COX5A, POLR2E Downregulated:GPX1, NDUFB3, NDUFA13, UQCR10, TGM2, COX7C | Interference with BDNF transcription/transport, destabilization of neuronal mitochondria |
Thermogenesis | 2.889e–4 | 0.026 | Upregulated:COX5A, ADCY7 Downregulated: GNAS, NDUFB3, NDUFA13, UQCR10, DPF3, COX7C, ADRB3, ADCY1-6, ADCY8-10 | Process triggered by hypothermia whereby chemical energy is converted to heat in adipose tissue to ensure normal cellular processes | |
Parkinson Disease | 5.085e–4 | 0.030 | Upregulated:CYCS, VDAC2, CASP9, CASP3, COX5A Downregulated:NDUFB3, NDUFA13, UQCR10, COX7C | Proteasome dysfunction, mitochondrial impairment and oxidative stress leading to loss of dopaminergic neurons | |
Ferroptosis | 7.290e–4 | 0.032 | Upregulated: VDAC2, CYBB Downregulated: SLC11A2, GCLC | Regulated cell death characterized by production of reactive oxygen species from iron and lipid peroxidation; involved in neurodegenerative disease | |
Unique to control | Ribosome | 2.035e–8 | 5.2e–6 | Upregulated (in Control):RPL7A, RPL11, RPL19, RPL23A, RPL30, RPL37, RPL38, RPS5, RPS8, RPS11, RPS15A, RPS20, RPS29, MRPL20 Downregulated in Control): UBA52, MRPL1 | Developmental increase in ribosomal biogenesis observed in controls but not CP subjects is consistent with prior reports of impaired ribosomal activity in CP |
